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INTRODUCTION 
             Hydatidiform mole (in greek hydatisia = drop of water, in latin 
mola= false conception) is the most common form of gestational 
trophoblastic disease occurring one in every 1000 pregnancies which 
results from abnormal fertilization and characterized by hydropic 
swelling of placental villi and trophoblastic hyperplasia. 
 
              Histopathologically there is considerable interobserver and 
intraobserver variability in distinguishing hydropic abortion from  
hydatidiform mole and complete hydatidiform mole from partial 
hydatidiform mole. The distinction is important because approximately 
10-30% of complete mole and 0.5-5% of partial moles can progress to 
persistent trophoblastic disease. 
 
         In addition, distinction of hydatidiform mole from Non molar 
pregnancy can be problematic in several situations, including: 
 (a) products of conception specimens (POCs) with abnormal villous 
morphology (a nonmolar type of villous abnormality having some 
morphologic features suggestive of a PHM (partial hydatidiform mole) 
but lacking the diandric triploidy required for a definitive diagnosis of 
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PHM, sometimes attributable to other genetic abnormalities such as 
trisomy)(1,2); 
 (b) early nonmolar abortuses with prominent trophoblastic hyperplasia; 
(c) hydropic abortuses; and (d) mosaic/chimeric conceptions.(3,4)   
Immunohistochemical study by using the markers 
• p57 will aid in distinguishing hydropic abortion from 
hydatidiform mole and complete hydatidiform mole from 
partial hydatidiform mole. 
• p21 will aid in assessing the malignant potential of molar 
pregnancy. 
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AIMS AND OBJECTIVES 
1) To analyse and review histopathologically proven cases of 
hydatidiform mole and hydropic abortions. 
2) To evaluate the efficacy of immunohistochemical markers in 
differentiating partial hydatidiform mole from complete 
hydatidiform mole. 
3) To evaluate role of immunohistochemical markers in assessing the 
malignant potential of molar pregnancies. 
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REVIEW OF LITERATURE 
Embryology 
Fertilization  of  ovum  by  a  spermatozoa  occurs  in  the  ampulla  
of  the  fallopian  tube  resulting  in  the  formation  of  zygote. Within  24  
hours,  the  zygote  undergoes  first  mitotic  division  to  form  morula  
containing  blastomeres. Morula   reaches  uterine  cavity  2  to  3  days  
after  fertilization  forming  blastocyst. 
Blastocyst  consists  of  peripheral  layer  of  blastomeres  forming  
the  trophoblast  with  a  mass of  cells  at  one  aspect,  the polar  
trophoblast,  bulging  into  the  central  lumen  and  known  as  inner  cell  
mass. 
           Trophoblast  along  with  maternal  contribution  gives  rise  to  
placenta  while  the  inner  cell  mass  develops  into  embryo.  
Trophoblast  gives  rise  to  two  layers,  an  inner  cytotrophoblast  layer  
and  outer  syncytiotrophoblast  layer.  A  third  type  of  trophoblast  
known  as  intermediate  trophoblast  also present.(1) 
             The  trabeculae  of  syncytiotrophoblast  and  intermediate  
trophoblast  between  the  lacunae  are  invaded  by  columns  of  
cytotrophoblastic  cells  called  primary  chorionic  villi.  Extra  
embryonic mesoderm now  invades  the  primary  villi, thus  develop  into  
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secondary  chorionic villi. When  mesenchymal  cores  of  villi  become  
vascularised  they  become  tertiary villi. 
 
Histology 
Placenta  consist  of  decidua  basalis,  decidua  capsularis,  and  
decidua  parietalis. 
            Once the maternal blood appear within the trophoblastic lacunae 
and the trabeculae between the  lacunae become increasingly robust and 
the stem villi form anchoring  points with the cytotrophoblastic shell. 
              Each villus consist of mesenchymal core containing capillaries 
of afferent and  efferent fetal blood vessels. The villi are invested by 
trophoblast which comprised of  an inner layer  of  cytotrophoblast  cells  
and broader outer syncytiotrophoblast layer. 
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Fig. 1.Schematic representation of trophoblastic subpopulations in 
placenta 
i) Cytotrophoblast – has single nucleus, clear to granular cytoplasm and 
well defined cell border. Mitotic activity is evident. Cytotrophoblast 
differentiates and gives rise to other types of trophoblast along two main 
pathways.(2,3) 
• Along one pathway, the cytotrophoblast continues its proliferation 
and fuses to form the overlying multinucleated 
syncytiotrophoblast. At the end of this process there will be  
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expansion of the surface area of chorionic villi in the developing 
placenta. 
•  In the second pathway, cytotrophoblast undergoes differentiation 
and gives rise to villous intermediate trophoblast in the 
trophoblastic columns and then in the placental site it gives rise to 
implantation site intermediate trophoblast  or chorionic-type of 
intermediate trophoblastin the chorion laeve. 
ii) Syncytiotrophoblast – has large multinucleate cellular mass with dense 
amphophilic cytoplasm often containing multiple vacuoles often contains 
brush border like cell membrane. Syncytiotrophoblast is composed of 
terminally differentiated cells, it synthesize and secrete a variety of 
pregnancy associated hormones that are thought to be critical in the 
establishment and maintenance of pregnancy. Do not show mitotic 
activity. 
iii) villous intermediate trophoblast – is mononucleate larger than 
cytotrophoblast with pale to clear cytoplasm and uniform round nuclei. 
 These cells undergoes proliferation in the proximal portion of the 
trophoblastic columns and plays major  role in maitanence of structural 
integrity of villi. It gives rise to implantation site and  chorionic type 
intermediate trophoblast. 
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Gestational Trophoblastic Disease(GTD) 
                 GTD is a spectrum of cellular proliferations which was arising 
from the placental villous trophoblast (4) and it is a heterogenous group of 
disease . 
 
WHO Classification of Gestational Trophoblastic Disease 
Neoplasms  
Choriocarcinoma                                                     9100/3 
Placental site trophoblastic tumour                         9104/1 
Epithelioid trophoblastic tumour                            9105/3 
 
Non neoplastic lesions 
Exaggerated placental site                                     
Placental site nodule and plaque 
 
Molar Pregnancies 
Hydatidiform mole                                             9100/0 
Complete                                                            9100/0 
Partial                                                                9103/0 
Invasive                                                             9100/1      
Abnormal (non molar) villous lesions  
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According to WHO, Gestational trophoblastic disease is broadly 
classified into molar and non molar lesions. The exaggerated placental 
site and the placental site nodule are the two benign entities included in 
this classification because they are trophoblastic lesions that must be 
distinguished from other entities with malignant potential. 
 
In fact, currently the management is largely medical and it is not 
necessary to classify these lesions morphologically. In the case of 
trophoblastic disease following a molar pregnancy, treatment is often 
conducted based on S.HCG titres and radiological diagnosis. 
  
Molar pregnancy includes hydatidiform mole (complete and 
partial) and invasive mole. Non molar lesions include choriocarcinoma, 
placental site trophoblastic tumour, epithelioid trophoblastic tumour. 
 
 
10 
 
 
Fig . 2. Flowchart representing cell of origin of various GTD and 
their IHC markers. 
 
Hydatidiform Mole (Molar Pregnancy) 
 Molar pregnancy is an abnormal form of pregnancy which is 
characterized by varying degrees of trophoblastic proliferations 
accompanying vesicular swelling of placental villi.  
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 A molar pregnancy starts when an egg is fertilized, but unlike in 
normal gestation, the placenta develops into an abnormal mass of grape 
like cysts. In case of complete molar pregnancy, there is no embryo or 
normal placental tissue, whereas in partial mole some fetal parts will be 
present.(5) 
 
 
Etio-Pathogenesis 
 
1. A complete molar pregnancy results when there is fertilization takes 
place by a single spermatozoa(90%)  with an empty ovum, which 
duplicates its chromosomal complement to become 46XX or empty ovum 
fertilized by two spermatozoa(10%)  resulting in a dispermic 46XX or 
46Xy mole and results in the development of only placental parts. A 
complete mole was completely of paternal origin, with a karyotype of 
usually 46 XX or 46XY.(6) 
2. A partial molar pregnancy results when there is fertilization takes place 
by  two  copies of paternal (diantric) genome  with a single ovum leading 
to triploidy (70% 69XXY, 27% 69XXX, 3% 69 XYY) and results in 
development of some  fetal parts.  However sometimes, a diploid 
karyotype may also exist.(7) 
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Epidemiology 
               Molar pregnancy incidence are increased in very young and 
older females of reproductive age and increased in those with a history of 
prior molar pregnancy. Incidence increased with increasing paternal age 
was reported in some studies [5].  
Bifulco C et al 2008 and Golfier F et al 2007 in their studies 
showed that incidence of complete mole outweighs partial mole.(8,9,10,11,12) 
In North America, Australia, New Zealand and Europe, the 
incidence of hydatidiform moles is approximately 0.57 – 1.1 per  1000 
pregnancies(13) . two forms of molar pregnancy(hydatidiform mole ) exists 
complete and partial molar pregnancies.Relatively higher incidence was 
reported in some areas of south Asia and Japan, which range from 2.0  
per 1000 pregnancies(14) In India and middle east the incidence is believed 
to be 1 in 160 pregnancies.(67) 
Genetics 
            Among the gestational trophoblastic disease molar pregnancy is a 
premalignant lesion, it also includes rare but agressive malignancies like 
choriocarcinoma and placental site trophoblastic tumour. In case of 
women with simpe molar pregnancy she should be reassured and close 
monitoring should be needed.(15-18) 
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Fig. 3.Genetic events occurring in normal conceptions, complete and 
partial molar pregnancies. (15, 16) 
 
   Risk of choriocarcinoma based on ploidy status. 
Risk factors for GTD 
• Very young  age(<15 years) and old age(>45 years)(19) 
• Complete molar pregnancies commonly has increased incidence in 
teenage women and women over 45 years old. Partial mole has no 
age predilection. 
14 
 
• Previous history of one molar pregnancy has 1 in 55  increased risk 
and history of two molar pregnancy had 1 in 10 risk for 
recurrence.(20) 
• Previous history of spontaneous abortion has 2-3 fold increased 
risk. 
• Reduced intake of beta carotene and animal fat. 
• Ovulation induction drugs 
Risk factors of complete mole 
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CLINICAL FEATURES 
Complete Mole 
• It typically presents with vaginal bleeding in the late first trimester 
or early phase of second trimester. 
• Absent fetal heart beat 
• Inappropriately enlarged uterus 
• Markedly elevated β – human chorionic gonadotrophin (β- hCG) 
level 
• Snow strom appearance in ultrasonogram. 
• Partial moles are  usually not suspected clinically, but it commonly 
present as missed abortions with late first-trimesterbleeding and a 
small uterus. 
• Grape like vesicles passing per vaginum 
• Hyperemesis 
• Early preeclampsia 
• Massive ovarian enlargement due to benign theca leutin cyst.(22) 
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Partial Mole 
• Patients with partial moles may have signs and symptoms similar 
to those seen in complete moles, but usually this is less likely. 
• Uterine size is generally small for dates. 
• Enlargement in excess of that expected for the gestational age is 
uncommon.   
• Patients with partial moles appear to have a missed abortion, and 
vaginal bleeding is the main presenting symptom.  
• Forty-two percent of patients with partial moles are at risk of pre-
eclampsia, which tends to occur later than in complete mole but it 
can be equally severe. 
• Serum beta-hCG levels often are in the low or normal range for 
gestational age.  
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Imaging studies 
Ultrasonogram 
• Snow storm pattern or bunch of grapes appearance in case of 
complete mole.(23) 
 
Fig. 3.USG showing snow storm appearance. 
• A growth restricted fetus and thick cystic placenta seen in case of 
partial mole.(23) 
Batorfi J, Vegh G, et al studied that non invasive molar pregnancy 
usually appears cystic and avascular in imaging than invasive molar 
pregnancy and choriocarcinoma which shows increased intratumoural 
blood flow.(24,25) 
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Serum markers 
HCG (human chorionic gonadotrophin) has been proved as an ideal 
marker for all forms of gestational trophoblastic disease, hence its 
measurement should be consider as an integral part for monitoring 
disease progression and management of gestational trophoblastic 
disease.(26) 
HCG is mainly produced by syncytiotrophoblast. In normal 
pregnancy, beta- hCG level ranges from 50,000 – 100,000 mIU/ml at 
about 10 wks of gestation and decreases to 10,000 – 20,000 mIU/ml by 
28 wks of gestation and it remains same there after until term. 
The below table represents rise in serum beta-hCG levels  
3 weeks LMP 5-50 mIU/ml 
4 weeks LMP 5-426 mIU/ml 
5 weeks LMP 18-7,340 mIU/ml 
6 weeks LMP 1,080 – 56,500 mIU/ml 
7-8 weeks LMP 7,650 – 229,000 mIU/ml 
9-12 weeks LMP 25,700 – 288,000 mIU/ml 
13-16  weeks LMP 13,300 – 254,000 mIU/ml 
17-24 weeks LMP 4,060 – 165,400 mIU/ml 
25 -40 weeks LMP 3,640 – 117,000 
Non pregnant 55 – 200 ng/ml 
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                     In a study by Mahrukh et al, theca leutin cysts were 
identified in 39% of cases out of which 17.64% patients had cysts greater 
than 6 cms in size. They usually produce symptoms like pressure 
symptoms and discomfort in many patients. In most of the cases, they 
spontaneously regress within 8 weeks. Beta hCG levels are often 100,000 
mIU/mL, and fetal heart tones are absent.28-31 
 
Pathophysiology: 
 A complete mole contains no fetal tissue.it can be divided into two types  
1. Androgenic complete mole (80%)  
2. Biparental complete mole. 
                    Androgenic complete mole derived from dispermy or 
duplication of paternal haploid chromosome (46xx) where as duplication 
of Y chromosome 46yy is extremely rare. Biparental complete mole 
which is rare. It contains both maternal and paternal genes, but only 
paternal genome is expressed due failure of maternal imprinting. 
 
                      The karyotype of complete mole is 46xx, the molar 
chromosomes are completely derived from father because haploid 23x 
from father replicates its own chromosomes due to fertilization of empty 
ovum. Whereas complete mole has chromosomes of parternal origin and 
mitochondrial DNA has maternal origin. 
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 Microscopically 
Complete Moles Have Two Key Features: 
1. Trophoblastic proliferation,  
2. Villous edema. 
                Most of the villus display centralcistern formation characterized 
by a prominent centralspace that is entirely acellular. Trophoblastic 
proliferation in complete hydatidiform mole was circumferential around 
the villus. The trophoblast of a complete mole always display cytologic 
atypia. 
                    Early complete mole does not have typical clinical 
presentation or classic sonogram appearance like complete mole and 
histopathologically it is difficult to differentiate from non molar gestation. 
In these situations immunohistochemistry will aid in diagnosis of 
complete mole. 
 
The microscopic features of an early complete mole are:  
(1)  Redundant or polypoid bulbous terminal villi;  
(2)  A labyrinthine network of villous stromal canaliculi;  
(3)  Hypercellular villous stroma with primitive stellate cells; 
 (4)  Atypical trophoblast lining the villi and in the implantation site. 
 (5)  Focal hyperplasia of cytotrophoblast and syncytiotrophoblast on 
both villi and the undersurface of the chorionic plate; [32, 33] and  
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6)  Increased villous stromal apoptosis.[32] 
                  Compared with the normal placentas, complete moles exhibit 
a higher level of apoptosis in cytotrophoblast, indicating a complex but 
delicate regulation of the cell population in complete moles. 
 
Partial mole 
The villi may be grossly evident and can be recognizable as molar, 
size will be smaller than those found in a complete mole and consist of 
immature placental tissue which are normal appearing admixed with 
occasional molar vesicles and also contains amnion, umbilical cord, some 
fetal parts usually present. 
In some cases a fetus or fetal membranes is present and there 
should be a mixture of edematous villi and small, relatively normal sized 
villi. Central cisterns are less conspicuous than in complete moles. 
                  The karyotype of partial mole is triplioid develops after 
fertilisation of apparently normal ovum by two spermatozoa. The fetuses 
with partial mole usually have congenital anomalies like syndactyly and 
cleft lip. 
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  Microscopic Features of Partial Mole Are The Following 
(1)   Two populations of villi (one hydropic and other small and fibrotic), 
 (2)  Irregular villi with geographic, scalloped borders with trophoblast 
inclusions, ,  
(3)  Enlarged villi with central cavitation and  
(4)  Minimal trophoblast hyperplasia (usually focal and involving 
syncytiotrophoblast)  
 
  Histopathologically there was considerable interobserver and 
intraobserver variability in distinguishing hydropic abortion from  
hydatidiform mole andcomplete hydatidiform mole from partial 
hydatidiform  mole. 
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The above table shows some of the differences between complete mole 
and partial mole. 
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Invasive Mole 
• Invasive mole is a form of complete hydatidiform mole in which 
the hydropic villi invades myometrium through direct tissue 
invasion or invade the blood vessels. Sometimes it invades 
extrauterine sites like lungs and paraspinal soft tissues. 
• It should be suspected  in patients having persistent elevation of 
beta-hCG levels even after removal of complete vesicular mole  
• The diagnosis should be made only on hysterectomy specimens to 
find out myometrial invasion. 
 
Histopathology of Invasive Mole 
             The characteristic feature of invasive mole is appearance of molar 
villi along with trophoblast within the myometrium or at extrauterine 
sites. There will be enlarged villi surrounded by hyperplastic trophoblast 
due to trophoblastic proliferation which range from minimal proliferation 
with mild atypia to marked proliferation with marked atypia.  
 
           Careful searching of the villi is needed to identify the lesion. Often 
invasive mole is diagnosed clinically based on persistent elevation of bête 
hCG after evacuation of molar pregnancy sometimes it is treated with 
chemotherapy even without a histopathological diagnosis.(35) 
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Choriocarcinoma 
                                Choriocarcinoma is a aggressive malignant 
trophoblastic  tumour arises from the gestational trophoblastic tissue  of 
any type , mostly from hydatidiform mole. Therotically it arises during 
implantation from the trophoblast of primitive blastocyst. Sometimes 
either “insitu” or intraplacental choriocarcinoma can also be found in the 
third trimester (36, 37).  
                              It consists of predominantly a biphasic proliferation of 
mononucleate trophoblast and syncytiotrophoblast  which 
morphologically recapitulates primitive trophoblast of the previllous 
stage during placental development. 
                   Choriocarcinomas can develop shortly after gestation or it can 
develop even after a long latency period of 10 years. It commonly present 
as abnormal uterine bleeding. Sometimes symptoms related to the site of 
metastasis may be the first indication of choriocarcinoma. Among other 
organs lungs is the common site of metastasis. 
                      Grossly it presents as circumscribed mass with central 
necrosis and hemorrhage. Microscopically, it has dimorphic pattern 
consisting of clusters and sheets of cytotrophoblast and intermediate 
trophoblast separated by syncytiotrophoblast.  
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                   The presence of intermediate trophoblast varies from 1 to 90 
%(38). Ocassionaly monomorphic variant may occur which predominantly 
composed of cytotrophoblast. 
 
MANAGEMENT OF GESTATIONAL TROPHOBLASTIC 
DISEASES
 
 
 
 
Hydatidiform mole diagnosed
Partial Mole
Medical termination of 
pregnancy and follow up
Complete Mole 
1.surgical evacuation
2.cervical softening with 
misoprostal followed by surgical 
evacuation
3.Hystrectomy in elderly women 
and follow up
4. No pregnancy for 2 years and 
use of contraceptive
5.Follow up with serum β - hCG.
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FIGO STAGING OF GESTATIONAL TROPHOBLASTIC 
DISEASE 
STAGE FEATURES 
I Disease confined to uterus 
II Disease extends outside the uterus, but limited to genital 
structures (adnexa,vagina, broad ligament) 
III Disease extends to the lungs 
IV All other metastatic sites 
IVA No risk factors 
IVB One risk factor 
IVC Two risk factors 
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Clinical Classification of Malignant Trophoblastic Disease: 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
NON METASTATIC GTD 
METASTATIC GTD 
Good Prognosis: 
• Low hCG level(<40,000mIU/ml serum beta- Hcg) 
• Symptoms present for less than 4 months 
• No brain or liver metastasis 
• No prior chemotherapy 
• Pregnancy event is not term delivery(i.e., 
mole,ectopic or spontaneous abortion) 
Poor Prognosis: 
• High pretreatment hCG level (>40,000mIU/ml 
serum beta – hCG) 
• Symptoms present for more tha 4 months 
• Brain or liver metastasis 
• Prior chemotherapeutic failure 
• Antecedent term pregnancy 
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ROLE OF IMMUNOHISTOCHEMISTRY IN MOLAR 
PREGNANCY AND OTHER GESTATIONAL TROPHOBLASTIC 
DISEASES 
                        Trophoblasts that include cytotrophoblasts, intermediate 
trophoblasts, and syncytiotrophoblasts stain strongly and diffusely with 
cytokeratins (AE1/AE3), inhibin,CD10,CK18,and 3β-hydroxy- D5-
steroid dehydrogenase (3βHSD). 
• All trophoblastic lesions express CK18 and HLA-G diffusely.  
• HCG expression in numerous syncytiotrophoblasts intimately 
admixed with mononuclear trophoblasts favors choriocarcinoma.  
• For lesions without numerous syncytiotrophoblasts, hPL 
expression without p63 favors a lesion composed of implantation-
site intermediate trophoblasts (exaggerated placental site versus 
placental site trophoblastic tumor [PSTT]).  
• p63 expression with variable hPL favors a lesion composed of 
chorionic-type intermediate trophoblast (placental site  nodule vs. 
epithelioid trophoblastic tumor [ETT]). 
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Fig .7.An algorithm using a panel of immunohistochemical markers 
is useful for the differential diagnosis of trophoblastic lesions. 
            
During first trimester the detection of abnormal gestations has led 
to diagnostic difficulties, because the increased villous size and 
trophoblastic proliferation are less pronounced in first trimester tissue 
compared to tissue derived from advanced gestations. The complete 
moles diagnosed in the first trimester have been referred to as “early” 
complete hydatidiform moles. 
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 IHC evaluation with antibodies against the p57 protein, a 
maternally transcribed gene product, has emerged as a useful adjunct to 
morphologic, flow cytometric, and cytogenetic study of molar tissue. 
               p57 protein is expressed in intermediate trophoblasts of 
complete moles, partial moles, and nonmolar abortuses. Complete 
hydatidiform moles lack p57 expression in cytotrophoblasts and villous 
stromal cells due to lack of maternally transmitted genome whereas it is 
expressed in cytotrophoblast and villous stromal cells of partial mole and 
non molar abortuses. 
 
                               p21-Activated kinases (PAKs) was first  discovered as 
effector molecules of Rho GTPases, Rac, and CDC42,4 now they are 
recognized as important mediators for a wide variety of cellular 
functions, including cell morphogenesis, motility, mitosis, apoptosis, and 
angiogenesis(46,47) 
                         PAK1 may play important roles in the pathogenesis of 
GTD including progress of HMs into GTN with even development of 
metastasis as well as tumorigenesis of CCA. overexpression and 
oncogenic effect of PAK1 has been earlier documented in various human 
malignancies, including glioblastoma,(48) breast,(49) colorectal,(53) 
ovarian,(50,52) and hepatocellular cancers.(51) PAK1 can also regulates 
cellular polarity and motility through cytoskeletal reorganization, and 
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hence affects cell invasion. Overexpression of PAK1 has been correlated 
with human breast cancer invasiveness and tumor grade. 
                    The paradoxical over expression of tumor suppressor genes 
has been reported in a variety of human cancers such as those of the 
esophagus, lung, breast and colon.The paradoxical increase in the tumor 
suppressor protein expression suggests the existence of a feedback loop 
between the oncogenes and the tumor suppressor genes; the main purpose 
of this is to maintain a homeostatic balance between the positive and 
negative regulators of the G1-S transition in the cell cycle. 
 
                          Owning to the proliferative property of cytotrophoblast 
and villous intermediate trophoblast, the presence of PAK1 
immunoreactivity in cytotrophoblast and villous intermediate trophoblast 
is an useful tool to assess the proliferation index which is high in 
complete mole, invasive mole and choriocarcinoma. 
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MATERIALS AND METHODS 
              This is a retrospective and prospective study done at at  ISO & 
Govt.Kasturba Gandhi  hospital, Madras Medical College, Chennai for a 
period of 2 years from June 2015 – May 2017. 
               Out of  5623 specimens received in at  ISO & GOVT.kasturba 
Gandhi  hospital, there were 412 specimens of products of conception. A 
statistically significant sample size of 52 cases are included in this study. 
Out of which 15 cases of  partial hydatidiform mole, 24 cases of complete 
hydatidiform mole, 11 cases of normal products of conception, 1 case of 
invasive mole and one case of choriocarcinoma are included in this study. 
Data Collection 
             Detailed history of the cases regarding age, symptoms, parity, 
radiological findings like ultrasonogram, history of previous pregnancy, 
details of gross characteristics  wereobtained from the patient files in the 
pathology registers.Freshly cut 4µ thick sections and Hematoxylin & 
Eosin stained sections of the paraffin tissue blocks of thsese specimens 
were reviewed. 
             52 cases were selected for this study and their representative 
formalin fixed paraffin embedded tissue samples were subjected to 
immunohistochemistry with a panel of 2 markers. 
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The results were recorded with photographs. 
Inclusion Criteria 
This study included  
• Patients with history of spontaneous abortions  
• Patients who are diagnosed as a case of molar pregnancy by 
histopathological examination. 
• Patients willing to participate in the study are included.  
Exclusion Criteria 
Other causes of abortions like  
1.Ectopic pregnancy 
2. Infection 
3.Uterine abnormality  
               All clinical data like age, parity and radiological findings like 
ultrasonogram findings were The hematoxylin and eosin stained and 
mounted slides were obtained from the archives of pathology laboratory. 
All slides were reviewed and the paraffin embedded tissue blocks were 
retrived from pathology lab and subjected to immunohistochemical 
studies. 
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Immunohistochemical Evaluation 
• Immunohistochemical analysis using p57 and p21 were done in 
paraffin embedded tissue samples using supersensitive polymer 
HRP system based on non biotin polymeric technology. 
• Sections with a thickness of 4 µ from selected formalin fixed 
paraffin embedded tissue samples were transferred onto gelatin 
coated slides. Heat induced antigen retrival was done. The antigen 
is bound with mouse monoclonal antibody (DAKO) against p57 
and p21 receptor and then detected by the addition of secondary 
antibody conjugated with horse radish peroxidase- polymer and 
Diaminobenzidine substrate. 
ANTIBODIES FOR IHC 
ANTIGEN VENDOR SPECIES DILUTION POSITIVITY
P57 Cell 
marque 
Mouse 
Mono 
prediluted Nuclear 
positivity 
P21 Cell 
marque 
Mouse 
Mono 
prediluted Nuclear 
positivity 
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The step by step procedure of IHC is listed below in detail. 
Preparation of Slides 
1. 4μ thick sections were cut from formalin fixed paraffin 
embedded tissue samples and transferred to charged slides 
2. The slides were incubated at 58ºC for overnight. 
3. The sections were deparaffinized in xylene for 10 minutes x 2 
changes. 
4. The sections were dehydrated with absolute alcohol for 10 
minutes x 2 changes. 
5. The slides were then immersed in tap water for 10 minutes. 
6. The slides were then immersed in distilled water for 2 minutes x 
2 changes. 
 
Antigen Retrieval 
7. Antigen retrieval was done with microwave oven in appropriate 
temperature with    appropriate buffer for 20 to 25 minutes. 
8. The slides were cooled to room temperature and washed in 
running tap water for 5 minutes.  
9. Apply peroxidase block over the sections for 10 minutes. 
10. Wash the slides in wash buffer for 5 minutes x 2 changes. 
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Antibody Application 
11. The sections were drained (without washing) and appropriate 
primary antibody was applied over the sections and incubated for 1 
hour. 
12. The slides were washed in wash buffer for 5 minutes x 2 changes. 
13. The slides were covered with CRF Anti – Polyvalent HRP Polymer 
for 30 minutes. 
14. The slides were washed in wash buffer for 5 minutes x 2 changes. 
 
Chromogen Application 
15. DAB substrate was prepared by diluting 1 drop of DAB chromogen 
to 1 ml of DAB buffer. 
16. DAB substrate solution was applied on the sections for 5 minutes. 
17. The slides were washed well in distilled water for 5 minutes. 
18. The sections were counterstained with Hematoxylin stain for 2 
seconds (1 dip). 
19. The slides were washed in running tap water for 3 minutes. 
20. The slides are air dried, cleared with xylene and mounted with DPX. 
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OBSERVATION AND RESULTS 
 
                 The total number of cases received in our institute is 5623 over 
a period of 2 years, from 2015 to 2017. There were 412 specimens of 
products of conception. A statistically significant sample size of 52 cases 
are included in this study.Out of which 15 cases  partial hydatidiform 
mole, 24 cases of complete hydatidiform mole, 11 cases of normal 
products of conception, 1 case of invasive mole and one case of 
choriocarcinoma were included in this study. 
                                                    TABLE I 
 
Histopathologicaldiagnosis Frequency Percent 
CHORIOCARCINOMA 1 1.9 
COMPLETE HYDATIDIFORM MOLE 24 46.2 
INVASIVE MOLE 1 1.9 
PARTIAL HYDATIDIFORM  MOLE 15 28.8 
PRODUCTS OF CONCEPTION 11 21.2 
Total 52 100.0 
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CHART I 
 
 
            It was found that among the gestational trophoblastic diseases 
complete mole has the highest incidence of 46.2%. The second most 
common was partial molar pregnancy accounting for 28.8%. 
choriocarcinoma and invasive mole has the least incidence of 1.9% each. 
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TABLE 3 
GA Weeks Frequency Percent 
upto 16 weeks 19 57.6% 
17-25 weeks 14 42.4% 
TOTAL 33 100.0 
 
CHART 3 
 
 
                      It was inferred from the table and chart that there is 
increased incidence of GTD ( 3case of complete mole,5 products of 
conception) among the early gestational age upto 16 weeks accounting 
for about 58% compared to  gestational age more than 16 wks. 
 
 
58%
42%
GA Weeks
upto 16 weeks
17-25 weeks
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TABLE 4 
HPE  DIAGNOSIS WITH TRIMESTER CORRELATION 
HPE DIAGNOSIS Trimester Total 
First 
trimester 
(up to 12 
weeks) 
Second  
trimester 
(above 12 
weeks) 
 
Complete 
Hydatidiform Mole 
Count 3 9 12 
% within 
HPE 25.0% 75.0% 100.0%
Partial 
Hydatidiform  Mole
Count 0 12 12 
% within 
HPE 0.0% 100.0% 100.0%
Products of 
Conception 
Count 5 4 9 
% within 
HPE 55.6% 44.4% 100.0%
Total 
Count 8 25 33 
% within 
HPE 24.2% 75.8% 100.0%
 
                 It is inferred from the above table that complete mole has first 
and second trimester incidence of 25% and 75 % respectively where as 
partial mole has 100% incidence in second trimester. 
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accounting for about 91.7%  whereas partial hydatidiform mole has 
higher incidence after 16 wks of gestation that is among 17 – 25 wks 
accounting for about 16.7%. Abortion from non molar gestation also has 
higher incidence upto 16wks of gestation accounting for about 66.7%. 
The age wise distribution of individual type of gestational 
trophoblastic disease is illustrated in ( Table 5, Chart 5)                                                   
TABLE 5 
 
AGE GROUP HISTOPATHOLOGICALDIAGNOSIS 
CORRELATION 
 
Age_Group Histopathologicaldiagnosis Total 
CC CHM    IM     PHM POC 
 
18-21 
years 
Count 0 9 0 1 2 12 
% 
within 
HPE 
0.0% 37.5% 0.0% 6.7% 18.2% 23.1% 
22-25 
years 
Count 0 11 0 2 3 16 
% 
within 
HPE 
0.0% 45.8% 0.0% 13.3% 27.3% 30.8% 
26-29 
years 
Count 0 3 0 9 3 15 
% with 
in HPE 0.0% 12.5% 0.0% 60.0% 27.3% 28.8% 
above 
29 
years 
Count 1 1 1 3 3 9 
% 
within 
HPE 
100.0
% 4.2% 
100.0
% 20.0% 27.3% 17.3% 
Total 
Count 1 24 1 15 11 52 
% 
within 
HPE 
100.0
% 
100.0
% 
100.0
% 
100.0
% 100.0% 100.0%
Pearson Chi-Square=27.247** p=0.007 
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                    Partial hydatidiform mole has higher incidence among 26-29 
years accounting for about 60% and it has relatively less incidence among 
18- 21 years. Non molar gestation has almost equal age distribution. 
 The age wise distribution of different types of gestational 
trophoblastic disease as inferred from our studies is illustrated in (TABLE 
5 and CHART 5). 
                   The incidence of individual type of GTD acoording to the 
parity of the patients was compared in the TABLE 6 , CHART 6 
TABLE 6 
HPE DIAGNOSIS WITH PARITY CORRELATION 
HPE Diagnosis Parity Total 
1.00 2.00 Primi 
 
Choriocarcinoma 
Count 1 0 0 1 
% within 
parity 9.1% 0.0% 0.0% 3.6% 
Complete 
Hydatidiform 
Mole 
Count 5 2 9 16 
% within 
parity 45.5% 28.6% 90.0% 57.1%
Partial 
Hydatidiform  
Mole 
Count 2 4 1 7 
% within 
parity 18.2% 57.1% 10.0% 25.0%
Products of 
Conception 
Count 3 1 0 4 
% within 
parity 27.3% 14.3% 0.0% 14.3%
Total 
Count 11 7 10 28 
% within 
parity 100.0% 100.0% 100.0% 100.0%
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TABLE 7 
SYMPTOMS WITH HISTOPATHOLOGICALDIAGNOSIS 
CORRELATION 
Symptoms Histopathologicaldiagnosis Total 
CC CHM PHM POC 
  
Bleeding PV
Count 0 6 3 3 12 
% 
within 
HPE 100.0% 40.00% 55.55% 75.00% 65.22% 
Hyperemesis
Count 0 2 2 0 4 
% 
within 
HPE 0.00% 13.33% 22.22% 0.00% 17.39% 
Lower 
Abdominal 
Pain 
Count 0 2 2 1 5 
% 
within 
HPE 0.00% 13.33% 22.22% 25.00% 21.74% 
% 
within 
HPE 0.00% 0.00% 11.11% 0.00% 4.35% 
Passage of 
Vesicles 
Count 0 5 0 0 5 
% 
within 
HPE 0.00% 33.33% 0.00% 0.00% 21.74% 
% 
within 
HPE 100.00% 0.00% 0.00% 0.00% 4.35% 
% 
within 
HPE 0.00% 0.00% 11.11% 0.00% 4.35% 
Total 
Count 1 15 9 4 29 
% 
within 
HPE 100.00% 100.00% 100.00% 100.00% 100.00%
 
      
patients w
accountin
accountin
symptoms
relatively 
 
 
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
     It was
ith comp
g for abo
g for 55
 are low
equal inc
C
H
O
R
IO
C
A
R
C
IN
O
M
A
0%
0%
 inferred 
lete mole 
ut 40% w
.55%. In
er abdo
idence. ch
C
O
M
PL
ET
E 
H
Y
D
AT
ID
IF
O
R
M
 
M
O
LE
40%
13
13
33
0
52
CHAR
from the 
commonl
hile parti
 partial 
minal pa
oriocarcin
PA
RT
IA
L 
H
Y
D
AT
ID
IF
O
R
M
  
M
O
LE
33%
7
22%
22%
20%
11%
T 7
above ta
y present
al mole p
hydatidif
in, hype
oma pres
PR
O
D
U
C
TS
 O
F 
C
O
N
C
EP
TI
O
N
5%
0%
5%
0%
ble and b
s with pas
resents w
orm mol
remsis, b
ents with
PASSA
LOWER
PAIN
HYPER
BLEED
ar diagra
sage of v
ith bleed
e the co
leeding 
 bleeding 
GE OF MO
 ABDOMI
EMESIS
ING PV
 
m that 
esicles 
ing pv 
mmon 
pv in 
pv. 
LES
NAL 
53 
 
TABLE 8  
FREQUENCY OF CLINICAL DIAGNOSIS 
Clinical_Diagnosis Frequency Percent 
Abortion 20 39.2% 
Complete Mole 2 3.9% 
Endometrial Carcinoma 1 2.0% 
Missed Abortion 2 3.9% 
Molar Pregnancy 17 51.0% 
 
 
CHART 8 
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         It is inferred from the above table and chart that among 52 cases in 
our study 51%  were clinically diagnosed as molar pregnancy  and 39.2%  
cases  were diagnosed as abortion. 
The comparision between parity with gestational age was given in 
Table 8, Chart 8. 
TABLE 9 
 Parity Total 
1.00 2.00 Primi 
Gestational  
age 
upto 16 
weeks 
Count 4 3 5 12 
% within 
parity 
57.1% 50.0% 100.0% 66.7%
17-25 
weeks 
Count 3 3 0 6 
% within 
parity 
42.9% 50.0% 0.0% 33.3%
Total 
Count 7 6 5 18 
% within 
parity 
100.0
% 
100.0% 100.0% 
100.0
% 
Pearson Chi-Square=3.537  P= 0.171 
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The below table show relevance of previous obstetrics history with 
occurrence of GTD 
TABLE 10 
HPE Previous_History Total 
A1 A2 A3 Molar 
Pregnancy 
+ 
 
Complete 
Hydatidiform 
Mole 
Count 3 2 1 3 9 
% 
within 
HPE 
33.3% 22.2% 11.1% 33.3% 100.0%
Partial 
Hydatidiform  
Mole 
Count 2 0 0 0 2 
% 
within
HPE 
100.0% 0.0% 0.0% 0.0% 100.0%
Products of 
Conception 
Count 1 0 0 0 1 
% 
within 
HPE 
100.0% 0.0% 0.0% 0.0% 100.0%
Total 
Count 6 2 1 3 12 
% 
within 
HPE 
50.0% 16.7% 8.3% 25.0% 100.0%
      
    It is inferred from the above table that 3 cases out of 24 cases of 
complete mole  has previous history of molar pregnancy accounting for 
about 12.5 %, so complete mole has increased predilection to occur after 
previous molar pregnancy and it has previous bad obstetric history.                             
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P57 EXPRESSION IN GTD 
The expression of p57 in different types of GTD was compared in 
(Table 10, Chart 9) 
TABLE 11 
 
HPE P57 Total 
Negative Strong Weak 
 
Choriocarcinoma 
Count 1 0 0 1 
% within 
HPE 100.0% 0.0% 0.0% 100.0%
Complete 
Hydatidiform Mole 
Count 22 2 0 24 
% within 
HPE 91.7% 8.3% 0.0% 100.0%
Invasive Mole 
Count 0 0 1 1 
% within 
HPE 0.0% 0.0% 100.0% 100.0%
Partial Hydatidiform 
Mole 
Count 0 14 1 15 
% within 
HPE 0.0% 93.3% 6.7% 100.0%
Products Of 
Conception 
Count 0 9 2 11 
% within 
HPE 0.0% 81.8% 18.2% 100.0%
Total 
Count 23 23 6 52 
% within 
HPE 44.2% 44.2% 11.5% 100.0%
 
Pearson Chi-Square=55.886**p<0.001 
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The below pie chart represents percentage of staining intensity of p 57 in 
complete mole and partial mole: 
CHART 11 
 
CHART 12 
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CHART 13 
 
It is inferred from the above table, bar diagram and pie chart that 
p57 expression was stronger in 14 out of 15 cases of partial mole 
accounting for about 93.3% and complete mole has predominantly 
negative expression of p57 in 22 out of 24 cases accounting for about 
91.7% and weak staining intensity in 2 out of 24 cases accounting for 
about 8.3%. the invasive mole  has weak staining intensity and 
choriocarcinoma stains negative with p57 immunohistochemistry. Non 
molar gestation has 81.8% strong positivity and 18.2 % weak staining 
intensity. 
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P21 EXPRESSION IN GTD 
 The below table shows the comparison of p21 marker expression  
in molar pregnancy, non molar gestation, choriocarcinoma and invasive 
mole.                                                       
TABLE 13 
HISTOPATHOLOGICALDIAGNOSIS WITH p21 SCORE 
CORRELATION 
Histopathologicaldiagnosis p21_score Total 
.00 1.00 2.00 3.00 
 
CC 
Count 0 0 0 1 1 
% within 
p21_score 0.0% 0.0% 0.0% 10.0% 1.9% 
CHM 
Count 1 3 12 8 24 
% within 
p21_score 50.0% 15.8% 57.1% 80.0% 46.2% 
IM 
Count 0 0 0 1 1 
% within 
p21_score 0.0% 0.0% 0.0% 10.0% 1.9% 
PHM 
Count 1 11 3 0 15 
% within 
p21_score 50.0% 57.9% 14.3% 0.0% 28.8% 
POC 
Count 0 5 6 0 11 
% within 
p21_score 0.0% 26.3% 28.6% 0.0% 21.2% 
Total 
Count 2 19 21 10 52 
% within 
p21_score 100.0% 100.0% 100.0% 100.0% 100.0% 
Pearson Chi-Square=28.854**p<0.001 
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The p21 expression with gestational age is compared in following 
table and chart 
TABLE 14 
GESTATIONAL AGE WITH P21 SCORE CORRELATION 
 
Gestational age p21_score Total 
.00 1.00 2.00 3.00 
 
upto 16 
weeks 
Count 0 1 15 3 19 
% within 
p21_score 0.0% 7.7% 93.8% 100.0% 57.6% 
17-25 
weeks 
Count 1 12 1 0 14 
% within 
p21_score 100.0% 92.3% 6.2% 0.0% 42.4% 
Total 
Count 1 13 16 3 33 
% within 
p21_score 100.0% 100.0% 100.0% 100.0% 100.0%
Pearson Chi-Square=25.383** p<0.00 
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DISCUSSION 
In this study 41 cases of histopathologically proven gestational 
trophoblastic lesions and 11 cases of products of conception were 
reviewed and evaluated with IHC marker P57KIP2 expression and p21 
expression to reevaluate the diagnosis and assess the neoplastic potential 
of the lesions.  
The incidence of complete mole was found to be the highest in the 
sample, accounting for 46%. Next higher incidence was found for partial 
hydatidiform mole accounting for about 28%. The incidence of 
choriocarcinoma and invasive mole was very rare that is only one case 
was reported inour institute for past 5 years. 
                   John R. Lurain, MD et al (2010) Chicago stated in his journal 
of epidemiology, pathology, clinical presentation and diagnosis of 
hydatidiform mole that the 2 risk factors for the occurrence of molar 
pregnancy are extremes of maternal age and prior molar pregnancy.  
               In our study complete mole tends to occur in younger age group 
and 12.5 % of complete mole has previous history of molar pregnancy. 
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                Choriocarcinoma  occurred  in 29 years in our study and it has 
previous  history abortion, it is significant because choriocarcinoma can 
occur following any gestational event. 
               In our study invasive mole occurred at 50years following the 
history of molar pregnancy 18 years back. 
              In our study, based on gestational age, complete mole tends to 
occur during first trimester and early weeks of second trimester compared 
to partial mole which occurs relatively more common during second 
trimester of gestation. 
             Abnormal vaginal bleeding in early pregnancy is the most 
common presentation in molar pregnancy(54). In our study also the 
common presenting complaints were bleeding per vaginum accounting 
for about 55%. 
Immunohistochemistry In Gestational Trophoblastic Disease 
  Due to marked interobserver and intraobserver variability in 
differentiating complete mole from partial mole and hydropic abortus, 
p57 marker was used.  
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Secondly, hydatidiform mole is prone for persistent trophoblastic 
disease in the form of invasive mole or choriocarcinoma which develop 
in approximately 15-20% with complete mole and 1-5% with partial 
mole(55-60). So, it is necessary to assess the malignant potential of molar 
pregnancy to prevent the occurrence of invasive mole and 
choriocarcinoma with the help of IHC marker p21. 
                     52 cases comprising of  41 cases of histopathologically 
proven gestational trophoblastic lesions and 11 cases of products of 
conception The formalin fixed paraffin embedded sections were subjected 
to immunohistochemical analysis with  p57 1nd p21. 
Expression of p57 in Normal Placenta, Partial Mole, Complete Mole, 
Invasive Mole and Chriocarcinoma 
                  Complete moles due to its lack of maternal genomic 
component, are not able to express the imprinted genes which are 
normally expressed by maternal allele results in negative expression for 
p57.  
                   Kihara et al. published the first report of perfect concordance 
between negative p57kip2 immunoreactivity and molar tissue of 
androgenetic origin. 
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But partial mole which has maternal genome will express p57 in 
cytotrophoblast and villous stromal cells. However, 
immunohistochemical analysis for p57 cannot distinguish a PHM from 
hydropic abortion.(61) 
                  In our study regarding the expression of  p 57 in already 
diagnosed complete mole by H&E, 22 out of total 24 cases CHM were 
negative ( 92%)  and remaining 2 cases showed  strong staining intensity 
( 8% )  and serial sections were reviewed. Multiple sections studied in 
those two cases showed features of PHM and hence diagnosis was 
revised. 
                     Regarding the expression of p57 IHC marker in partial 
moles 14 out of 15 cases shows strong staining intensity for p57( 93.3% ) 
and 1 out of 15 showed weak staining intensity (6.7%) which is 
statistically significant. Based on this expression of p57, it serves as a 
useful adjunct to differentiate between complete and partial mole. 
                  M. Paul et al. (2010) in USA(62)  found that in his study all 
cases of normal product of conception  showed strong positivity for 
p57KIP2 IHC marker. 
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                    In our study, P57 showed variable expression with 9 out of 
11 cases showing strong positivity (81%) and 2 out of 11(19%) cases 
showed weak positivity. But based on histopathological feature we can 
differentiate between partial mole from normal placenta. 
          In our Institute we had a rare case of partial mole with singleton 
live fetus.      This has the most uncommon  occurrence  (0.005%-0.01%)  
of  a  singleton  normal fetus  with  partial  molar  placenta. It  has  been  
reported  only  seven  times  in  extensively searched  medical  literature. 
Expression of P21 In Normal Placenta, Partial Mole, Complete Mole, 
Invasive Mole and Choriocarcinoma 
                  p21 is a cell proliferation marker and  the actively dividing 
cells show increased expression of p21 immunostaining. This is the 
reason for its increased expression in first trimester compared to second 
trimester.PAK1(p21 activated kinases)  immunoreactivity in 
cytotrophoblast and villous intermediate trophoblast  demonstrated its 
proliferative capacity. 
                    Gestational trophoblastic diseases are characterized by 
abnormally high levels of trophoblast  proliferation. Choriocarcinoma is a 
highly malignant tumor that may arise from the trophoblasts of any type 
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of gestational event, and most commonly seen in the case of a complete 
mole. In choriocarcinoma, certain G1/S inhibitors, like p21 is over 
expressed.  
In our study, 19 cases were of first trimester. Out of which 15 cases 
showed 2+ staining intensity accounting for about 93.8% and 3 cases 
showed 3+ staining pattern. But in second trimester p21 expression was 
decreased, 12 cases out of 14 shows 1+ staining intensity. Hence, most of 
first trimester pregnancy shows moderate expression of p21 and most of 
second trimester pregnancy sows weak expression of p21. 
      In case of molar pregnancy in our study, compete mole has 
increased expression of p21 compared to partial mole. 
              Invasive mole and choriocarcinoma shows strong staining 
pattern with p21 indicating the highly malignant behavior of these GTD. 
In many other studies also it has been reported that p21 displays 
immunoreactivity the first-trimester cytotrophoblasts(64,65,66) and p21 
shows an increased expression in gestational trophoblastic diseases. 
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SUMMARY 
 
                In the present study 24 complete moles, 15 partial moles, 11 
non molar gestation, one choriocarcinoma and one invasive mole 
accounting to 52 cases were included. An attempt is made to check the 
correlation between histopathological diagnosis and 
immunohistochemical evaluation of molar pregnancy. 
                     Also, the malignant potential of molar pregnancy is 
evaluated using immunohistochemistry. 
                     It is found that among the gestational trophoblastic diseases 
complete mole has the highest incidence of 46.2%. the second most 
common was partial molar pregnancy accounting for 28.8%. 
choriocarcinoma and invasive mole has the least incidence of 1.9% each. 
  First highest incidence of GTD is among the age group of 22- 25 
years accounting for about 31%. Second highest incidence was found 
among 26- 29 years accounting for 29%. Above 29 years of age there was 
decreased incidence of gestational trophoblastic disease.  
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          Complete mole has increased incidence during early period of 
gestation accounting for 91% whereas partial hydatidiform mole has 
higher incidence in second trimester accounting for about 83%.  
     The immunohistochemistry marker p57 expression was positive 
in partial mole accounting for about 100% and complete mole had 
negative expression in 91.1%.  Invasive mole and choriocarcinoma were 
negative p57 immunohistochemistry. Non molar gestation had 81% 
strong positivity and 19 % weak staining intensity. 
Complete  mole, choriocarcinoma and invasive mole had increased 
expression of p21 compared to partial mole and non molar gestation 
indicating their increased cell proliferation. 
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CONCLUSION 
• P57 is used as a potential marker in differentiating partial mole and 
hydropic abort us from complete mole, hence avoiding unnecessary 
DNA analysis. 
 
• The over expression of p21 in complete mole, invasive mole and 
choriocarcinoma indicates its association with proliferative 
activity, hence it’s a useful marker to assess the malignant potential 
of molar pregnancy. P21 targeted therapy is available in the 
market, so it can be used as a therapeutic marker. 
 
 
 
 
 BIBILIOGRAPHY 
REFERENCES 
1. Robert J.Kurman, Lora Hedrick Ellenson, Brigitte M. Ronnett, 
Blaustein’s pathology of the female genital tract, 6:1077-1079 
2. Shih I-M (2007) Gestational trophoblastic neoplasia—pathogenesis 
and potential therapeutic targets. Lancet Oncol 8:642–650. 
3. Shih I-M, Kurman RJ (2001) Placental site trophoblastic tumor–past 
as prologue. Gynecol Oncol 82:413–414 
4. John R. Lurain, MD, John I. Brewer Trophoblastic Disease Center, 
Northwestern University Feinberg School of Medicine, 250 
E.Superior St., Suite 05-2168, Chicago, IL 60611. 
5.  Petignat P, Billieux MH, Blouin JL, Dahoun S, Vassilakos P. Is 
genetic analysis useful in the routine management of hydatidiform 
mole? Hum Reprod., Feb 2003; 18(2): 243–9. 
6. Hancock BW, Tidy JA. Current management of molar pregnancy. J 
Reprod Med., May 2002; 47(5): 347–54. 
7. Lee D, Contreras M, Robson SC, Rodeck CH, Whittle MJ. 
Recommendations for the use of anti-D immunoglobulin for Rh 
prophylaxis.British Blood Transfusion Society and the Royal 
 College of Obstetricians and Gynaecologists. Transfus Med., Mar 
1999; 9(1): 93–7. 
8.  Bifulco C, Johnson C, Hao L, Kermalli H, Bell S, Hui P (2008) 
Genotypic analysis of hydatidiform mole: an accurate and practical 
method of diagnosis. Am J Surg Pathol 32:445–451. 
9.  Czernobilsky B, Barash A, Lancet M (1982) Partial moles: a 
clinicopathologic study of 25 cases. Obstet Gynecol 59:75–77. 
10.  Golfier F, Raudrant D, Frappart L, Mathian B, Guastalla JP, Trillet- 
Lenoir V, Vaudoyer F, Hajri T, Schott AM (2007) First 
epidemiological data from the French Trophoblastic Disease 
Reference Center. Am J Obstet Gynecol 196(172):e171–e175. 
11.  Jacobs PA, Hunt PA, Matsuura JS, Wilson CC, Szulman AE (1982) 
Complete and partial hydatidiform mole in Hawaii: cytogenetics, 
morphology and epidemiology. Br J Obstet Gynaecol 89:258–266. 
12.  McConnell TG, Murphy KM, Hafez M, Vang R, Ronnett B (2009) 
Diagnosis and subclassification of hydatidiform moles using p57 
immunohistochemistry and molecular genotyping: validation and 
prospective analysis in routine and consultation practice settings 
with development of an algorithmic approach. Am J Surg Pathol 
33:805–817. 
 13. Atrash HK, Hogue CJR, Grimes DA.Epidemiology of hydatidiform 
mole during early gestation. Am J Obstet Gynecol 1986;154:906-9. 
14. Altieri A, Franceschi S, Ferlay J, Smith J, La Vecchia C (2003) 
Epidemiology and aetiology of gestational trophoblastic diseases. 
Lancet Oncol 4:670–678. 
15. Curry SL, Hammond CB, Tyrey L, Creasman WT, Parker RT. 
Hydatidiform mole: diagnosis, management, and longterm followup 
of 347 patients. Obstet Gynecol., Jan 1975; 45(1): 1–8.  
16.  Kohorn EI. The new FIGO 2000 staging and risk factor scoring 
system for gestational trophoblastic disease: description and clinical 
assessment. Int J Gynecol Cancer., 2001; 11: 73–7.  
17.  Curry SL, Schlaerth JB, Kohorn EI, Boyce JB, Gore H, Twiggs LB, 
et al. Hormonal contraception and trophoblastic sequelae after 
hydatidiform mole. A Gynecologic Oncology Group study. Am J 
Obstet Gynecol., 1989; 160: 805–9.  
18.  Berkowitz RS, Im SS, Bernstein MR, Goldstein DP. Gestational 
trophoblastic disease: subsequent pregnancy outcome, including 
repeat molar pregnancy. J Reprod Med., 1998; 43: 81–6.  
19.  Soper JT, Clarke-Pearson DL, Berchuck A, Rodriguez G, Hammond 
CB.5-day methotrexate for women with metastatic gestational 
trophoblastic disease. Gynecol Oncol., 1994; 54: 76–9.  
 20.  Deng L, Yan X, Zhang J, Wu T. Combination chemotherapy for 
high-risk gestational trophoblastic tumour. Cochrane Database Syst 
Rev., Apr 2009; (2): CD005196.  
21.  Rustin GJ, Newlands ES, Lutz JM, Holden L, Bagshawe KD, Hiscox 
JG, et al. Combination but not single-agent methotrexate 
chemotherapy for gestational trophoblastic tumors increases the 
incidence of second tumors. J Clin Oncol, 1996; 14: 2769–73. 
22.  Garner EI, Goldstein DP, Feltmate CM, Berkowitz RS (2007) 
Gestational trophoblastic disease. Clin Obstet Gynecol 50:112–122 
23. Wagner B, et al.Gestational trophoblastic disease: Radiologic- 
Pathologic correlation. Radiographics., January 1996; 16(1). 
24. Shigeru Sasaki. Clinical presentation and management of molar 
pregnancy. Best Practice and Research Clinical Obstetrics and 
Gynecology., December 2003; 17(6): 885-892.  
25.  Batorfi J, Vegh G, et al. How long should patients be followed after 
molar pregnancy? Analysis of serum hCG follow-up data. Eur J 
Obstet Gynecol Reprod Biol., Jan 2004; 112(1): 95-7. 
26. Cole LA, Khanlian SA,Muller CY, Giddings A, Kohorn E, 
Berkowitz R (2006) Gestational trophoblastic diseases: 3.Human 
chorionic gonadotropin- free beta-subunit, a reliable marker of 
placental site trophoblastic tumors. Gynecol Oncol 102:160–164. 
 27. Hsieh TY, Hsu KF,Kuo PL,Huang SC (2008)Uterine 
choriocarcinoma accompanied by an extremely high human 
chorionic gonadotropin level and thyrotoxicosis. J Obstet Gynaecol 
Res 34:274–278. 
28. Curry SL, Hammond CB, Tyrey L, et al. Hydatidiform mole: 
diagnosis, management, and long-term follow-up of 347 patients. 
Obstet Gynecol 1975;45:1-8. 
29. Hou JL, Wan XR, Xiang Y, et al. Changes in clinical features in 
hydatidiform mole: analysis on 113 cases. J Reprod Med 
2008;53:629-33. 
30.  Kohorn EI. Molar pregnancy: presentation and diagnosis. Clin 
Obstet Gynecol 1984;27:181-9. 
31.  Soto-Wright V, Bernstein MR, Goldstein DP, et al. The changing 
clinical presentation of complete molar pregnancy. Obstet Gynecol 
1995;86:775-9. 
32.  Keep D, Zaragoza MV, Hassold T, Redline RW (1996) Very early 
complete hydatidiform mole. Hum Pathol 27:708–713. 
33.  Mosher R, Goldstein DP, Berkowitz R, Bernstein M, Genest DR 
(1998) Complete hydatidiform mole. Comparison of 
clinicopathologic features, current and past. J Reprod Med 43:21–27. 
 34.  Kim MJ, Kim KR, Ro JY, Lage JM, Lee HI (2006) Diagnostic and 
pathogenetic significance of increased stromal apoptosis and 
incomplete vasculogenesis in complete hydatidiform moles in very 
early pregnancy periods. Am J Surg Pathol 30:362–369. 
35.  Lurain JR, Brewer JI. Invasive mole. Semin Oncol 1982;9:174-80. 
36. Datta T, Banerjee AK, Adeyemo AK, McCullough WL, Duncan A 
(2007) Intraplacental choriocarcinoma associated with pregnancy 
continuum: a diagnostic dilemma. J Obstet Gynaecol 27:731–732. 
37.  Fox H, Laurini RN (1988) Intraplacental choriocarcinoma: a report 
of two cases. J Clin Pathol 41:1085–1088. 
38.  Shih I-M, Kurman RJ (1996) Expression of melanoma cell adhesion 
molecule in intermediate trophoblast. Lab Invest 75:377–388. 
39.  Castrillon DH, Sun DQ, Weremowicz S, et al: Discrimination of 
complete hydatidiform mole from its mimics by 
immunohistochemistry of the paternally imprinted gene product 
p57KIP2.Am J Surg Pathol. 25:1225–1230, 2001. 
40. Fisher RA, Hodges MD, Rees HC, et al: The maternally 
transcribedgene p57(KIP2) (CDNK1C) is abnormally expressed 
inboth androgenetic and biparental complete hydatidiform 
moles.Hum Mol Genet. 11:3267–3272, 2002. 
 41. Fukunaga M: Immunohistochemical characterization of p57 (KIP2) 
expression in early hydatidiform moles. Hum Pathol.33:1188–1192, 
2002. 
42.  Genest DR, Dorfman DM, Castrillon DH: Ploidy and imprintingin 
hydatidiform moles. Complementary use of flow cytometry and 
immunohistochemistry of the imprinted gene productp57KIP2 to 
assist molar classification.J Reprod Med. 47:342–346, 2002. 
43.  Hoffner L, Dunn J, Esposito N, et al: P57KIP2 immunostainingand 
molecular cytogenetics: Combined approach aids in diagnosisof 
morphologically challenging cases with molar phenotypeand in 
detecting androgenetic cell lines in mosaic/chimeric 
conceptions.Hum Pathol. 39:63–72, 2008. 
44.  Keep D, Zaragoza MV, Hassold T, et al: Very early complete 
hydatidiform mole. Hum Pathol. 27:708–713, 1996. 
45.  Kim MJ, Kim KR, Ro JY, et al: Diagnostic and pathogenetic 
significance of increased stromal apoptosis and incomplete 
vasculogenesis in complete hydatidiform moles in very early 
pregnancy periods. Am J Surg Pathol. 30:362–369, 2006. 
46. Bokoch GM: Biology of the p21-activated kinases. Annu Rev 
Biochem 2003, 72:743–781 
 47.  Kumar R, Gururaj AE, Barnes CJ: p21-activated kinases in cancer. 
Nat Rev Cancer 2006, 6:459–471. 
48.  Aoki H, Yokoyama T, Fujiwara K, Tari AM, Sawaya R, Suki D, 
Hess KR, Aldape KD, Kondo S, Kumar R, Kondo Y: 
Phosphorylated Pak1 level in the cytoplasm correlates with shorter 
survival time in patients with glioblastoma. Clin Cancer Res 2007, 
13:6603–6609 
49.  Bagheri-Yarmand R, Mandal M, Taludker AH, Wang RA, 
Vadlamudi RK, Kung HJ, Kumar R: Etk/Bmx tyrosine kinase 
activates Pak1 and regulates tumorigenicity of breast cancer cells. J 
Biol Chem 2001, 276:29403–29409 
50.  Schraml P, Schwerdtfeger G, Burkhalter F, Raggi A, Schmidt D, 
Ruffalo T, King W, Wilber K, Mihatsch MJ, Moch H: Combined 
array comparative genomic hybridization and tissue microarray 
analysis suggest PAK1 at 11q13.5-q14 as a critical oncogene target 
in ovarian carcinoma. Am J Pathol 2003, 163:985–992 
51.  Ching YP, Leong VY, Lee MF, Xu HT, Jin DY, Ng IO: P21-
activated protein kinase is overexpressed in hepatocellular carcinoma 
and enhances cancer metastasis involving c-Jun NH2-terminal kinase 
activation and paxillin phosphorylation. Cancer Res 2007, 67:3601– 
3608. 
 52.  Siu MK, Wong ES, Chan HY, Kong DS, Woo NW, Tam KF, Ngan 
HY, Chan QK, Chan DC, Chan KW, Cheung AN: Differential 
expression and phosphorylation of Pak1 and Pak2 in ovarian cancer: 
effects on prognosis and cell invasion. Int J Cancer 2009 127:21–31 
53.  Carter JH, Douglass LE, Deddens JA, Colligan BM, Bhatt TR, 
Pemberton JO, Konicek S, Hom J, Marshall M, Graff JR: Pak-1 
expression increases with progression of colorectal carcinomas to 
metastasis. Clin Cancer Res 2004, 10:3448–3456. 
54.  Rustin GJ, Newlands ES, Lutz JM, Holden L, Bagshawe KD, Hiscox 
JG, et al. Combination but not single-agent methotrexate 
chemotherapy for gestational trophoblastic tumors increases the 
incidence of second tumors. J Clin Oncol, 1996; 14: 2769–73.  
55. Berkowitz RS, Goldstein DS. Clinical practice:molar pregnancy. N 
Engl J Med 2009;360:1639-45. 
56. Lurain JR, Brewer JI, Torok E, Halpern B.Natural history of 
hydatidiform mole after primaryevacuation. Am J Obstet Gynecol 
1983;145:591-5. 
57.  Feltmate CM, Batorfi J, Fulop V, et al. Humanchorionic 
gonadotropin follow-up in patientswith molar pregnancy: a time for 
reevaluation.Obstet Gynecol 2003;101:732-6. 
 58. Hancock BW, Nazir K, Everard JE. Persistentgestational 
trophoblastic neoplasia afterpartial hydatidiform mole: incidence and 
outcome.J Reprod Med 2006;51:764-6. 
59. Feltmate CM, Growdon WB, Wolfberg AJ,et al. Clinical 
characteristics of persistent gestationaltrophoblastic neoplasia after 
partial hydatidiformmolar pregnancy. J Reprod Med2006;51:902-6. 
60. Goto S, Yamada A, Ishizuka T, Tomodo Y.Development of 
postmolar trophoblastic diseaseafter partial molar pregnancy. 
Gynecol Oncol 1993;48:165-70. 
61. Robin D. LeGallo, MD,1 Edward B. Stelow, MD,1 et al. " Diagnosis 
of Hydatidiform Moles Using p57 Immunohistochemistry and HER2 
Fluorescent In Situ Hybridization". Am J Clin 
Pathol;129(2008):749-755 .  
62.  Fox H. Aging of the placenta. Arch Dis Child Fetal Neonatal. Ed 77, 
1997; 171-5. 
63.  Fox H. Differential diagnosis of hydatidiform moles. Gen Diagn 
Pathol 1997; 143: 117-25. 
64. Fulop V, Mok SC, Genest DR, Gati I, Doszpod J, Berkowitz RS. 
p53,p21, Rb and mdm2 oncoproteins.Expression in normal 
placenta,partial and complete mole, and choriocarcinoma.J Reprod 
Med1998; 43: 119-27. 
 65.  Genbacev O, McMaster MT, Fisher SJ. A repertoire of cell cycle 
regulators whose expression is coordinated with human 
cytotrophoblast differentiation. Am J Pathol 2000; 157: 1337-51. 
66.  Quenby S, Brazeau C, Drakeley A, Lewis-Jones DI, Vince G. 
Oncogeneand tumour suppressor gene products during trophoblast 
differentiationin the first trimester. Mol Hum Reprod 1998; 4: 477-
81. 
67.  Daftary SN, Padubidri VG. Trophoblastic diseases. In: Padubidri 
VG, Daftary SN (eds). Shaw’s Textbook of Gynaecology, 13th edn 
New Delhi. Elseiver India Ltd. 2004:248-59. 
 
 
  
 
 
 
 
 
 
  
 CERTIFICATE - II 
 
This is to certify that this dissertation work titled “THE ROLE 
OF IMMUNOHISTOCHEMICAL MARKERS IN 
EVALUATING THE MALIGNANT POTENTIAL OF 
MOLAR PREGNANCIES” of the candidate Dr. C. SUGANTHI 
with registration Number 201513008 for the award of M.D in the branch 
of  PATHOLOGY. I personally verified the urkund.com website for the 
purpose of plagiarism Check. I found that the uploaded thesis file 
contains from introduction to conclusion pages and result shows 2 
Percentage of plagiarism in the dissertation. 
 
 
 
Guide & Supervisor Sign with Seal 
 
 
  
 PARTIAL MOLE 
 
 
                                    
 
 
 
               
 
 
 
 
 
 
Chorionic villi showing papillary infoldings and focal 
trophoblastic proliferation 
P57 show strong 
positivity 
P21 show 1+ staining intensity 
 COMPLETE MOLE 
        
                                    
 
 
 
 
              
 
 
 
 
 
 
Chorionic villi showing central cistern formation 
P57 – negative staining P21 showing 2+ staining pattern 
 INVASIVE MOLE 
 
 
 
 
      
    
 
 
 
 
 
 
Invasive mole showing chorionic villi 
invading the myometrium 
P57 -  negative staining pattern P21 – 3+ staining pattern 
 CHORIOCARCINOMA 
 
 
 
 
 
           
 
 
 
 
 
 
P57 – negative staining pattern P21 show 3+ staining pattern 
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 ANNEXURE - 1 
 
TNM classification of gestational trophoblastic disease 
Primary tumour (T) 
TNM Category FIGO Stage Pathologic Findings 
Tx  Primary tumour cannot be 
assessed 
T0  No evidence of primary tumour 
T1 I Tumour confined to uterus 
T2 II Tumour extends to other genital 
structures(ovary,tube,vagina,broad 
ligaments) by metastatis or direct 
extension 
 
Distant metastasi (M) 
TNM category FIGO Stage Pathologic findings 
M0  No distant metastasis 
M1  Distant metastasis 
M1a III GTN extends to the lungs with 
or without known genital 
metastases 
M1b IV All other metastases 
 
 
 
 
  
 ANNEXURE – 2 
WHO Classification of gestational trophoblastic disease 
Neoplasms  
Choriocarcinoma                                                     9100/3 
Placental site trophoblastic tumour                         9104/1 
Epithelioid trophoblastic tumour                            9105/3 
 
Non neoplastic lesions 
Exaggerated placental site                                     
Placental site nodule and plaque 
 
Molar pregnancies 
Hydatidiform mole                                             9100/0 
Complete                                                            9100/0 
Partial                                                                9103/0 
Invasive                                                             9100/1      
 
Abnormal (non molar ) villous lesions  
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PROFORMA: 
 
 
CASE NO:         
 
BIOPSY NO: 
 
NAME:         
 
AGE: 
 
SEX:          
 
IP NO: 
 
CLINICAL DIAGNOSIS: 
 
SYMPTOMS: 
 
RISK FACTORS IF ANY: 
 
USG FINDINGS: 
 
 
PROCEDURE DONE: 
 
MACROSCOPY: 
 
MICROSCOPY: 
 
 
IHC PROFILE: 
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molar pregnancies and to plan for additional treatment measures.  
• We are selecting certain cases and if your specimen is found eligible, 
we may beusing your specimen to perform extra tests and special 
studies which in any way donot affect your final report or 
management. 
• The privacy of the patients in the research will be maintained 
throughout the study. Inthe event of any publication or presentation 
resulting from the research, no personally identifiable information 
will be shared. 
• Taking part in this study is voluntary. You are free to decide whether 
to participate inthis study or to withdraw at any time; your decision 
will not result in any loss ofbenefits to which you are otherwise 
entitled. 
• The results of the special study may be intimated to you at the end of 
the study periodor during the study if anything is found abnormal 
which may aid in the managementor treatment. 
 
Signature of investigator    Signature of participant 
     Date: 
 INFORMED CONSENT FORM 
Title of the studY  :“THE ROLE OF IMMUNOHISTOCHEMICAL 
MARKERS IN  EVALUATING THE MALIGNANT POTENTIAL 
OF MOLAR PREGNANCIES’’  
Name of the Participant   :  
Name of the Principal (Co-Investigator) : 
Name of the Institution : ISO & Govt kasturba Gandhi 
hospital, madras medical college. 
Name and address of the sponsor / agency (ies) (if any) : 
Documentation of the informed consent 
I _____________________________ have read the information in this 
form (or it has been read tome). I was free to ask any questions and 
they have been answered. I am over 18 years of age and, exercising 
my free power of choice, hereby give my consent to be included as a 
participant in “THE ROLE OF IMMUNOHISTOCHEMICAL 
MARKERS IN  EVALUATING THE MALIGNANT 
POTENTIAL OF MOLAR PREGNANCIES’’  
1. I have read and understood this consent form and the information 
provided to me. 
2. I have had the consent document explained to me. 
3. I have been explained about the nature of the study in which the 
product of conception will be subjected to immunocytochemistry 
and immunohistochemistry examination. 
4. I have been explained about my rights and responsibilities by the 
investigator. I have the right to withdraw from the study at any time. 
5. I have been informed the investigator of all the treatments I am 
taking or have taken in the past ________ months including any 
native (alternative) treatment. 
 6. I hereby give permission to the investigators to release the 
information obtained from me as result of participation in this study 
to the sponsors, regulatory authorities, Govt. agencies, and IEC. I 
understand that they are publicly presented. 
7. I have understood that my identity will be kept confidential if my 
data are publicly presented 
8. I have had my questions answered to my satisfaction. 
9. I have decided to be in the research study. 
I am aware that if I have any question during this study, I should 
contact the investigator. By signing this consent form I attest that the 
information given in this document has been clearly explained to me and 
understood by me, I will be given a copy of this consent document. 
For participants: 
Name and signature / thumb impression of the participant (or legal 
representative if participant incompetent) 
Name _________________________ Signature_________________ 
Date________________ 
Name and Signature of impartial witness (required for illiterate patients): 
Name _________________________ Signature_________________ 
Date________________ 
 
Address and contact number of the impartial witness: 
Name and Signature of the investigator or his representative obtaining 
consent: 
Name _________________________ Signature_________________ 
Date__________ 
 
